D57.09 Insurance Policy Changes

ICD-10 D57.09 is officially defined as "Hb-SS disease with crisis with other specified complication." code D57.09 is referenced in 5 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D57.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 16, 2026Medium impact
Lovotibeglogene Autotemcel (Lyfgenia) (CPB 1053, reviewed 2025-12-31)
Aetna's Clinical Policy Bulletin for lovotibeglogene autotemcel (Lyfgenia) addresses this one-time gene therapy for sickle cell disease for commercial medical plans. Aetna considers a single dose medically necessary only when the member meets all of the listed initial approval criteria, and precertification is required through National Medical Excellence. The drug must be prescribed by or in consultation with a hematologist, and Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Exagamglogene Autotemcel (Casgevy) (CPB 1052, reviewed 2025-12-31)
Aetna's Clinical Policy Bulletin 1052 covers Casgevy (exagamglogene autotemcel) as a one-time single-dose intravenous infusion for sickle cell disease or transfusion-dependent beta thalassemia when the member meets the listed criteria, and the drug receives dedicated GCIT review for Commercial and Medicare lines of business. Precertification is required for all Aetna participating providers and members in applicable plan designs. The criteria cover members 12 or older with a confirmed genotype, a history of severe vaso-occlusive episodes or transfusion needs, eligibility for stem cell transplant without a matched 10/10 HLA-related donor, and for sickle cell disease, an inadequate response, intolerance or contraindication to hydroxyurea. Aetna considers all other indications experimental, investigational, or unproven.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with no substantive changes to coverage criteria. The policy continues to cover this gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity requirements. No billing or documentation workflow changes are required.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
This is a reissue of Independence Blue Cross policy 08.02.14a with no substantive changes to coverage criteria for Casgevy (exagamglogene autotemcel), a gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients 12 years and older. The policy maintains existing medical necessity requirements, including prior treatment attempts, documented severe vaso-occlusive crises, and eligibility criteria. Billing teams should verify this reissue does not affect current claim processing but confirm HCPCS code J3392 remains the appropriate billing code.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with NO CONTENT CHANGES on 07/01/2025. This is an informational reissue confirming continued coverage for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity criteria. No billing workflow changes are required.

Watch D57.09

Get one email when a payer policy names D57.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D57.09?

There are 5 tracked policy changes affecting code D57.09, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D57.09?

Payers that have issued tracked updates for code D57.09 include: Aetna, Independence Blue Cross.

How do I get notified when code D57.09 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D57.09. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D57.09?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Lovotibeglogene Autotemcel (Lyfgenia) (CPB 1053, reviewed 2025-12-31)

Exagamglogene Autotemcel (Casgevy) (CPB 1052, reviewed 2025-12-31)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

What insurance policy changes affect code D57.09?

Which payers have updated policy for code D57.09?

How do I get notified when code D57.09 policy changes?

Why do payers change policies for code D57.09?